However, the pegylated formulations of IFN-α showed partial or complete tumor response in 8 of 10 AIDS-KS patients, all were on combination antiretroviral therapy (cART) at peg-IFN initiation [95]. This evidence concerns the gene IFNA2 and Kaposi's sarcoma.